MarketCap
Facebook
X
TelegramQuartalsbericht 2022-Q3
hinzugefügt 10.11.2022
Oyster Point Pharma ROA 2011-2026 | OYST
ROA Jährlich Oyster Point Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -45.22 | -35.63 | -31.92 | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -31.92 | -45.22 | -37.59 |
ROA Vierteljährlich Oyster Point Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -95.45 | -104.51 | -79.92 | -58.85 | -32.93 | -44.16 | -43.34 | -37.52 | -35.63 | -38.17 | -37.96 | -37.64 | -31.92 | -88.47 | -196.71 | -189.21 | -186.59 | -116.27 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -31.92 | -196.71 | -80.85 |
ROA anderer Aktien in der Pharmaeinzelhändler
| Name | ROA | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-31.06 | $ 3.85 | 3.22 % | $ 9.26 B |  Australia |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
6.32 | $ 327.75 | -1.69 % | $ 42.9 B | USA |
|
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
-27.33 | $ 7.65 | 3.1 % | $ 75.6 M | USA |
 |
Allakos
ALLK
|
-76.23 | - | - | $ 28.6 M | USA |
 |
Burford Capital Limited
BUR
|
5.51 | $ 4.68 | -0.95 % | $ 756 M |  Britain |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M |  Israel |
 |
Cabaletta Bio
CABA
|
-101.68 | $ 3.44 | 1.03 % | $ 346 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
-218.41 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-1008.51 | - | -2.5 % | $ 5.88 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
6.02 | $ 21.62 | -0.28 % | $ 1.01 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-24.24 | - | - | $ 3.45 B | USA |
 |
BioNTech SE
BNTX
|
65.02 | $ 99.29 | -0.18 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 3.1 | -4.32 % | $ 5.1 M | Israel |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
ContraFect Corporation
CFRX
|
-315.07 | - | -5.16 % | $ 5.39 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
-1.42 | $ 1.41 | -9.03 % | $ 363 M | USA |
 |
Galectin Therapeutics
GALT
|
-157.87 | $ 2.36 | -7.81 % | $ 151 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-52.23 | $ 4.18 | -1.5 % | $ 447 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-3.73 | $ 24.23 | -1.42 % | $ 3.08 B | USA |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
26.14 | - | -4.8 % | $ 255 M | USA |
 |
Grifols, S.A.
GRFS
|
1.38 | $ 8.68 | -0.12 % | $ 6.83 B |  Spain |
 |
Autolus Therapeutics plc
AUTL
|
-48.81 | $ 1.48 | -0.67 % | $ 394 M | Britain |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
3.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Checkpoint Therapeutics
CKPT
|
-752.78 | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
-57.1 | - | -16.75 % | $ 25.8 M | USA |
 |
AVROBIO
AVRO
|
12.03 | - | 1083.1 % | $ 745 M | USA |
 |
Clearside Biomedical
CLSD
|
-95.49 | - | - | $ 25.3 M | USA |
 |
Celldex Therapeutics
CLDX
|
-44.38 | $ 33.44 | -1.27 % | $ 2.22 B | USA |
 |
bluebird bio
BLUE
|
-34.23 | - | - | $ 546 M | USA |